10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||||||||||||||
| ||||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
AMGEN INC | |||
Ticker: AMGN Fiscal Year: 2022 | |||
Consolidated Statements of Cash Flows | |||
Period Ending Dec 31, 2022 10-K (Filed: Feb 9, 2023) | |||
| (In Millions, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
| Cash flows from operating activities: | |||
| Net income | $ 6,552 | 5,893 | 7,264 |
| Depreciation, amortization and other | 3,417 | 3,398 | 3,601 |
| Stock-based compensation expense | 401 | 341 | 330 |
| Deferred income taxes | (1,198) | (453) | (287) |
| Acquired in-process research and development | 0 | 1,505 | 0 |
| Adjustments for equity method investments | 891 | 33 | 65 |
| Loss on divestiture | 567 | 0 | 0 |
| Other items, net | (176) | (262) | (260) |
| Changes in operating assets and liabilities, net of acquisitions: | |||
| Trade receivables, net | (746) | (429) | (427) |
| Inventories | (742) | (165) | (215) |
| Other assets | 258 | (237) | 129 |
| Accounts payable | 154 | (69) | 45 |
| Accrued income taxes, net | (647) | (854) | (249) |
| Long-term tax liabilities | 229 | 204 | (482) |
| Other liabilities | 761 | 356 | 983 |
| Net cash provided by operating activities | 9,721 | 9,261 | 10,497 |
| Cash flows from investing activities: | |||
| Purchases of marketable securities | (2,587) | (8,900) | (8,477) |
| Proceeds from sales of marketable securities | 98 | 4,403 | 2,597 |
| Proceeds from maturities of marketable securities | 1,120 | 8,831 | 4,381 |
| Purchases of property, plant and equipment | (936) | (880) | (608) |
| Cash paid for acquisitions, net of cash acquired | (3,839) | (2,529) | 0 |
| Purchases of equity method investments | (18) | (157) | (3,219) |
| Proceeds from Divestiture of Businesses, Net of Cash Divested | 130 | 0 | 0 |
| Other | (12) | (35) | (75) |
| Net cash (used in) provided by investing activities | (6,044) | 733 | (5,401) |
| Cash flows from financing activities: | |||
| Net proceeds from issuance of debt | 6,919 | 4,945 | 8,914 |
| Extinguishment of debt | (297) | 0 | 0 |
| Repayment of debt | 0 | (4,150) | (6,450) |
| Repurchases of common stock | (6,360) | (4,975) | (3,486) |
| Dividends paid | (4,196) | (4,013) | (3,755) |
| Other | (103) | (78) | (90) |
| Net cash used in financing activities | (4,037) | (8,271) | (4,867) |
| (Decrease) increase in cash and cash equivalents | (360) | 1,723 | 229 |
| Cash and cash equivalents at beginning of year | 7,989 | 6,266 | |
| Cash and cash equivalents at end of year | 7,629 | 7,989 | 6,266 |
| External Links | |
| AMGEN INC (AMGN) Fiscal Year 2022 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |